Financing ·
Pays $20M cash and issues 4.43M shares to BMS to clear varegacestat milestone obligations
IMNMImmunome Inc.
Immunome Inc. entered into Amendment No. 4 to its License Agreement with Bristol-Myers Squibb Company, removing all future milestone and royalty payment obligations for the drug varegacestat (formerly AL102). In exchange, Immunome paid $20 million in cash and issued 4,425,487 shares of common stock. The company must file a resale registration statement by November 16, 2026. Immunome Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer.